Summary

KEY FINDINGS
The China dry eye disease market is expected to grow at a CAGR of 5.81% from 2024 to 2032. The market was valued at $384.43 million in 2023, with projected revenue reaching $643.91 million by 2032. The market’s expansion is driven by a combination of factors, including the rising prevalence of dry eye diseases, lifestyle changes, and an increasing demand for dry eye disease treatment products.
MARKET INSIGHTS
The growth in China’s dry eye disease market can be attributed to the increasing prevalence of dry eye disease across various demographics, influenced by factors such as extended screen exposure and rising pollution levels. These modern lifestyle habits, coupled with the growing geriatric population, contribute to the increased incidence of dry eye disease symptoms. The aging population is more vulnerable to decreased tear production and other factors that exacerbate dry eye diseases.
Furthermore, conditions like diabetes and autoimmune disorders, which are well-known dry eye disease causes, are becoming more prevalent in China, thereby expanding the patient base. Rising awareness about dry eye disease diagnosis and improved access to dry eye disease treatment options are also contributing to the market’s growth. The market is also experiencing rising demand for dry eye disease treatment devices and drugs, particularly those targeting anti-inflammatory drugs and other therapeutic options, as more advanced products become available.
In the China dry eye disease market, eye drops are among the most common treatment options for managing dry eye disease symptoms, particularly in mild to moderate cases. These products offer a convenient and immediate solution for relieving irritation, dryness, and discomfort associated with dry eye diseases. As the prevalence of dry eye disease continues to rise, the demand for eye drops for dry eye disease is expected to grow steadily.
One challenge facing the China dry eye disease market is the underdiagnosis of dry eye diseases, as many individuals delay seeking medical attention for early-stage symptoms. However, increased public awareness campaigns and the availability of advanced diagnostic tools are expected to improve early detection rates.
The China dry eye disease market is expected to grow, driven by the increasing demand for dry eye disease treatment, rising awareness about the condition, and ongoing innovations in therapeutic and diagnostic products. Key players such as Alcon, Bausch Health Companies Inc, and Johnson & Johnson are actively introducing advanced eye drops and treatment devices, positioning the market for development over the forecast period.
SEGMENTATION ANALYSIS
The China dry eye disease market segmentation includes distribution channel, dosage, type, and product. The product segment includes anti-inflammatory drugs, secretagogues, punctal plugs, artificial tears, and other products. The anti-inflammatory drugs segment is further classified into corticosteroid, cyclosporine, and other anti-inflammatory drugs.
Secretagogues are modern treatments for dry eye conditions, available in both oral and topical forms, and are frequently recommended as first-line and second-line therapies. A key driver of this segment’s growth is the awareness campaigns led by vision science and optometry institutions, promoting the use of secretagogues in both emerging and developed markets. Notably, 2% rebamipide ophthalmic suspension and 3% diquafosol sodium ophthalmic solution are topical secretagogues available globally. Meanwhile, commonly used oral secretagogues, such as cevimeline and pilocarpine, work by activating acetylcholine receptors in the lacrimal and salivary glands to stimulate secretion.
Artificial tears are also a prevalent treatment for dry eye disease, often recommended as the initial approach by doctors. They provide temporary relief from irritation and burning caused by eye dryness, primarily by reducing tear osmolarity. Over-the-counter artificial tears are widely accepted due to their low cost and accessibility across various population segments.
Additionally, corticosteroids are effective anti-inflammatory medications for relieving symptoms of moderate to severe dry eye disease. They are particularly beneficial for short-term use and are often prescribed in acute cases. However, prolonged use of corticosteroids can lead to significant side effects, such as cataract progression and increased intraocular pressure.
COMPETITIVE INSIGHTS
Some of the prominent companies in the China dry eye disease market include Bausch Health Companies Inc, Johnson & Johnson, Otsuka Pharmaceutical Co Ltd, Allergan Plc (Acquired by AbbVie), etc.
Johnson & Johnson (J&J) is a global company that researches, develops, manufactures, and sells pharmaceutical products and medical devices. It provides treatments for immune disorders, cancer, neurological conditions, infectious diseases, and cardiovascular and metabolic disorders.
The company also offers medical devices for cardiovascular, orthopedic, neurovascular care, surgery, and vision care, which includes dry eye disease treatment products. With its presence across multiple regions, including the US, Europe, Asia-Pacific, Africa, and Latin America, J&J plays a crucial role in distributing its products to retailers, wholesalers, healthcare providers, and hospitals worldwide. Its headquarters are located in New Brunswick, New Jersey, the United States.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING FOR CHINA DRY EYE DISEASE MARKET
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DOSAGE
7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS
8. MARKET BY DISTRIBUTION CHANNEL
8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ALCON
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. BAUSCH HEALTH COMPANIES INC
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. JOHNSON & JOHNSON
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. NOVALIQ GMBH
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. SANTEN PHARMACEUTICAL CO LTD
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCTS LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. NOVARTIS AG
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCT LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. PRODUCT LIST
9.2.7.3. STRENGTHS & CHALLENGES